GLP-1 Receptor Agonists: Changing the scales of human health, Hilary Henly, RGA

Glucagon-like peptide 1 receptor agonists (GLP-1s), which were initially developed to help manage and treat diabetes and later used to treat obesity, are now showing significant potential to help prevent and treat other conditions. RGA’s Hilary Henly, Global Medical Researcher, explains how GLP-1s may be poised to become an integral part of treating a range chronic diseases – from cardiovascular disease to cancer – and could improve all-cause mortality rates.